- Home
- MCW vs PHVS Comparison
MCW vs PHVS Comparison
Compare MCW & PHVS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | MCW | PHVS |
|---|---|---|
| Founded | 1996 | 2015 |
| Country | United States | Switzerland |
| Employees | N/A | N/A |
| Industry | | Biotechnology: Pharmaceutical Preparations |
| Sector | | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 2.0B | 1.8B |
| IPO Year | 2021 | 2020 |
Fundamental Metrics
Financial Performance| Metric | MCW | PHVS |
|---|---|---|
| Price | $7.05 | $29.29 |
| Analyst Decision | Hold | Buy |
| Analyst Count | 11 | 11 |
| Target Price | $7.28 | ★ $41.82 |
| AVG Volume (30 Days) | ★ 2.0M | 235.1K |
| Earning Date | 04-29-2026 | 05-12-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 47.62 | N/A |
| EPS | ★ 0.31 | N/A |
| Revenue | ★ $1,051,731,000.00 | N/A |
| Revenue This Year | $7.92 | N/A |
| Revenue Next Year | $7.05 | N/A |
| P/E Ratio | $22.82 | ★ N/A |
| Revenue Growth | ★ 5.73 | N/A |
| 52 Week Low | $4.61 | $15.51 |
| 52 Week High | $7.81 | $30.87 |
Technical Indicators
Market Signals| Indicator | MCW | PHVS |
|---|---|---|
| Relative Strength Index (RSI) | 61.03 | 52.54 |
| Support Level | $6.95 | $24.73 |
| Resistance Level | $7.13 | N/A |
| Average True Range (ATR) | 0.03 | 1.53 |
| MACD | -0.00 | 0.07 |
| Stochastic Oscillator | 37.14 | 51.69 |
Price Performance
Historical ComparisonAbout MCW Mister Car Wash Inc.
Mister Car Wash Inc is a car wash brand offering express exterior and interior cleaning services. Express Exterior Locations offers express exterior cleaning services and Interior Cleaning Locations offers both express exterior and interior cleaning services. The company recognizes revenue from activities related to providing car wash services at its car wash locations that are geographically diversified throughout the United States and have similar economic characteristics and nature of services.
About PHVS Pharvaris N.V.
Pharvaris NV is a late-stage biopharmaceutical company which is engaged in developing novel, oral bradykinin B2 receptor antagonists to prevent and treat HAE attacks. By directly pursuing this clinically therapeutic target with novel small molecules, With positive data in both Phase 2 prophylaxis and studies in HAE, Pharvaris is developing deucrictibant. Pharvaris is currently enrolling a pivotal Phase 3 study for the treatment of HAE attacks and plans to initiate a pivotal Phase 3 study of deucrictibant for the prevention of HAE attacks.